CEL-SCI Corporation
CVM

$40.64 M
Marketcap
$0.64
Share price
Country
$-0.03
Change (1 day)
$3.23
Year High
$0.54
Year Low
Categories

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

marketcap

Revenue of CEL-SCI Corporation (CVM)

Revenue in 2023 (TTM): $

According to CEL-SCI Corporation's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of CEL-SCI Corporation

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $ $-3,958,334 $-27,560,550 $-32,194,302 $-32,365,855
2022 $ $-3,883,386 $-31,736,259 $-36,700,681 $-38,267,691
2021 $ $-499,000 $-33,963,021 $-36,361,109 $-39,187,563
2020 $558.66 K $540.82 K $-26,825,326 $-30,255,244 $-32,223,336
2019 $462.75 K $450.1 K $-19,561,577 $-22,134,640 $-24,692,724
2018 $476.56 K $465.64 K $-16,122,115 $-31,837,205 $-31,837,205
2017 $69.02 K $-563,980 $-9,698,098 $-14,363,287 $-14,363,287
2016 $285.06 K $267.61 K $-9,081,102 $-11,466,498 $-11,466,498
2015 $657.38 K $638.19 K $-32,727,989 $-34,674,646 $-34,674,646
2014 $264 $-15,002 $-26,970,739 $-27,366,265 $-27,366,265
2013 $160 $-12,521 $-17,388,993 $-9,170,947 $-9,170,947
2012 $254.61 K $244.24 K $-14,681,628 $-15,477,310 $-15,477,310
2011 $956.15 K $956.15 K $-24,858,047 $-25,712,343 $-25,712,343
2010 $153.3 K $153.3 K $9.63 M $10.48 M $10.48 M
2009 $80.09 K $80.09 K $-40,094,902 $-40,512,107 $-40,910,030
2008 $5.07 K $5.07 K $-9,048,127 $-7,712,900 $-7,703,415
2007 $57.04 K $57.04 K $-7,995,602 $-8,484,027 $-9,629,657
2006 $125.46 K $125.46 K $-5,073,943 $-7,814,960 $-7,939,210
2005 $269.93 K $269.93 K $-3,890,347 $-3,092,267 $-3,039,607
2004 $325.48 K $325.48 K $-3,888,105 $ $-4,199,722
2003 $318.3 K $318.3 K $-1,647,505 $ $-6,371,498
2002 $384.94 K $384.94 K $-3,990,023 $ $-8,342,244
2001 $376.22 K $376.22 K $-10,818,429 $-10,733,679 $-10,733,679
2000 $402.01 K $402.01 K $-8,297,943 $-8,478,397 $-8,478,397
1999 $400 K $400 K $-7,300,000 $-7,500,000 $-7,500,000
1998 $100 K $100 K $-6,200,000 $-6,300,000 $-6,400,000
1997 $400 K $400 K $-7,900,000 $-8,100,000 $-8,200,000
1996 $300 K $300 K $-6,300,000 $-6,300,000 $-6,300,000
1995 $100 K $100 K $-3,400,000 $-3,800,000 $-3,900,000
1994 $100 K $100 K $-4,400,000 $-4,200,000 $-4,400,000
1993 $1000 K $-300,000 $-2,000,000 $-2,400,000 $-2,400,000
1992 $400 K $-100,000 $-1,100,000 $-1,700,000 $-1,700,000
1991 $100 K $ $-500,000 $-1,100,000 $-1,200,000
1990 $100 K $100 K $-400,000 $-800,000 $-900,000
1989 $100 K $100 K $-800,000 $-1,000,000 $-1,100,000
1988 $100 K $100 K $-1,300,000 $-1,500,000 $-1,300,000
1987 $100 K $-800,000 $-1,500,000 $-1,700,000 $-1,700,000
1986 $100 K $-1,300,000 $-2,300,000 $ $-2,900,000